Recipharm has made an equity investment in Synthonics Inc. and purchased $2.0 million of stock in the company. A further $2.0 million of stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016. The companies have also entered into a joint development agreement under which Synthonics gains access to Recipharm’s drug development, marketing and manufacturing expertise in exchange for a royalty payment on certain Synthonics compounds. Synthon...